Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235259 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
A Phase 2 study, sponsored by Xigen.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT02235259: Completed Phase 2 study, sponsored by Xigen.
NCT02235259 is a Phase 2 study that has completed, run by Xigen. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02235259, a Phase 2 study, has completed, sponsored by Xigen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period
Interventions
- DRUG Placebo
- DRUG XG-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT02235259 record still lists
NCT02235259 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02235259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02235259 about?
NCT02235259 is a clinical study titled "Efficacy and Safety of XG-104 for the Treatment of Dry Eye". The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period
What is the current status of trial NCT02235259?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2014-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02235259?
The interventions under investigation include: Placebo (DRUG), XG-104 (DRUG).
Who is sponsoring clinical trial NCT02235259?
This trial is sponsored by Xigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02235259's enrollment target sits among peer trials
260 210th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia